biostudies-literatureBifarin OOVeterans AdministrationBLRD VAEvans County Cares FoundationNCI NIH HHSCook Family Foundation3629-3641https://www.ebi.ac.uk/biostudies/studies/S-EPMC9847475biostudies-literatureUnknown20(7)Renal cell carcinoma (RCC) is diagnosed through expensive cross-sectional imaging, frequently followed by renal mass biopsy, which is not only invasive but also prone to sampling errors. Hence, there is a critical need for a noninvasive diagnostic assay. RCC exhibits altered cellular metabolism combined with the close proximity of the tumor(s) to the urine in the kidney, suggesting that urine metabolomic profiling is an excellent choice for assay development. Here, we acquired liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) data followed by the use of machine learning (ML) to discover candidate metabolomic panels for RCC. The study cohort consisted of 105 RCC patients and 179 controls separated into two subcohorts: the model cohort and the test cohort. Journal of proteome researchMachine Learning-Enabled Renal Cell Carcinoma Status Prediction Using Multiplatform Urine-Based Metabolomics.PMC9847475I01 BX003367R01 CA2186641 I01 BX003367-01Master VASah SFernandez FMPetros JAOgan KArnold RSEdison ASBifarin OORoberts DLGaul DABergquist SHfalseMachine Learning-Enabled Renal Cell Carcinoma Status Prediction Using Multiplatform Urine-Based Metabolomics.Renal cell carcinoma (RCC) is diagnosed through expensive cross-sectional imaging, frequently followed by renal mass biopsy, which is not only invasive but also prone to sampling errors. Hence, there is a critical need for a noninvasive diagnostic assay. RCC exhibits altered cellular metabolism combined with the close proximity of the tumor(s) to the urine in the kidney, suggesting that urine metabolomic profiling is an excellent choice for assay development. Here, we acquired liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) data followed by the use of machine learning (ML) to discover candidate metabolomic panels for RCC. The study cohort consisted of 105 RCC patients and 179 controls separated into two subcohorts: the model cohort and the test cohort. 2021-01-01T00:00:00Z2021 Jul2025-04-21T15:12:57.8Z2025-04-21T15:12:57.8ZS-EPMC98474753416109210.1021/acs.jproteome.1c00213